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and insulin release in islet b-cells, positioning ghrelin as a modulator of insulinotropic GLP-1.
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Insulin secretion from pancreatic islet b-cells is regulated by a
variety of inhibitory and stimulatory gastro-intestinal hormones
including ghrelin and glucagon-like peptide-1 (GLP-1). Ghrelin, a
stomach-derived 28-amino acid hormone discovered as the endog-
enous ligand for the growth hormone (GH) secretagogue-receptor
(GHS-R) [1,2], potently stimulates GH release and feeding and
exhibits positive cardiovascular effects, suggesting its possible
clinical application [3]. Ghrelin, GHS-R [4–6] and ghrelin O-acyl-
transferase (GOAT), the enzyme that acylates the third serine res-
idue of ghrelin [7,8], are all expressed in pancreatic islets [9].
Administration of ghrelin inhibits insulin release and increases
blood glucose levels in rodents [6,10] and humans [11]. Ghrelin
suppresses glucose-induced insulin release in perfused pancreas
and isolated islets and glucose-induced increases in cytosolic
Ca2+ concentration ([Ca2+]i) in single b-cells [6,12]. Conversely,
ghrelin immunoneutralization, GHS-R antagonists and ghrelin
deﬁciency all enhance glucose-induced insulin release from per-
fused pancreas and isolated islets [12]. Administration of GHS-Rchemical Societies. Published by Eantagonist [6,12,13] and GOAT inhibitors [14] enhances insulin re-
sponses and lowers glucose concentrations during glucose toler-
ance tests (GTTs). These ﬁndings indicate that ghrelin is an
important regulator of insulin release and glucose homeostasis
[15,16].
We previously reported that ghrelin stimulates pertussis toxin
(PTX)-sensitive Gai2, an inhibitory subtype of GTP-binding proteins
[17], attenuates cAMP-PKA signaling, and activates 2.1 subtype of
voltage-dependent K+ (Kv2.1) channels, thereby inhibiting glu-
cose-induced [Ca2+]i increases and insulin release in islet b-cells
[18]. These results suggested that ghrelin could counteract the ac-
tion of GLP-1, a physiological incretin hormone that activates
cAMP and Ca2+ signaling in islet b-cells to promote glucose-in-
duced insulin release [19–21]. Clarifying the interaction between
ghrelin and GLP-1, the physiological insulinostatic and insulino-
tropic hormones, on the b-cell signaling pathway and insulin re-
lease, would promote the understanding of the physiological
regulation of insulin release and glycemia and of the effectiveness
of anti-diabetic medicines, GLP-1 agonists and inhibitors of dipep-
tidyl peptidase-4 (DPP-4). This study aimed to clarify whether
exogenous ghrelin counteracts and blockade of endogenous ghrelin
enhances GLP-1 effects on insulin release, cAMP and [Ca2+]i signal-
ing in rat islet b-cells.lsevier B.V. All rights reserved.
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2.1. Animals
Male Wistar rats (Japan SLC, Hamamatsu) were housed under a
controlled temperature (26 C) and photoperiod (12L:12D). The
rats received pellet-type food (CE-2, Japan Clea, Tokyo, Japan)
and tap water ad libitum. The animal protocols were in accordance
with the Japanese Physiological Society’s guidelines for animal
care.
2.2. Preparation of pancreatic islets and single b-cells
Islets of Langerhans were isolated by collagenase digestion from
male Wistar rats aged 8 weeks, as reported previously [6,22] with
slight modiﬁcation. Animals were anaesthetized by intraperitoneal
injection of pentobarbitone at 80 mg/kg, followed by injection of
collagenase at 1.05 mg/ml (Sigma–Aldrich) into the common bile
duct. Collagenase was dissolved in 5 mM Ca2+ containing HEPES-
added Krebs–Ringer bicarbonate buffer (HKRB) solution (in mM):
NaCl 129, NaHCO3 5.0, KCl 4.7, KH2PO4 1.2, CaCl2 2.0, MgSO4 1.2
and HEPES 10 at pH 7.4 with NaOH, supplemented with 0.1% BSA
when needed. Pancreas was dissected out and incubated at 37 C
for 16 min. Islets were hand collected under a microscope and
were immediately used for the measurement of insulin secretion
and cAMP production. For b-cell experiments, islets were dispersed
into single cells in Ca2+ free HKRB, and the single cells were plated
sparsely on coverslips and maintained for 1 day at 37 C in an
atmosphere of 5% CO2 and 95% air in Eagle’s minimal essential
medium containing 5.6 mM glucose supplemented with 10% fetal
bovine serum, 100 lg/ml streptomycin, and 100 U/ml penicillin.
2.3. Measurements of insulin release and cAMP productions in isolated
islets of rats
For measurements of insulin release, each tube containing 12–
15 islets was incubated for 1 h at 37 C in HKRB with 2.8 mM glu-
cose for stabilization, followed by test incubation for 1 h in HKRB
with 2.8 or 8.3 mM glucose. For the experiments with GOAT inhib-
itor, islets were preincubated for 24 h with 5 lM GO-CoA-Tat, a
peptide-based bisubstrate analog that lowers acyl ghrelin level
[14], or vehicle in the culture medium. In cAMP measurements,
each tube containing 10 islets was incubated for 1 h in HKRB with
2.8, 5.6 or 8.3 mM glucose containing 500 lM 3-isobutyl-1-meth-
ylxanthine (IBMX), an inhibitor of phosphodiesterase (PDE) (Sig-
ma–Aldrich), to avoid degradation of cAMP in the samples.
Insulin release and total cAMP content in isolated islets were
determined by ELISA kit (Morinaga, Yokohama, Japan) and EIA kit
(GE Healthcare, Buckinghamshire, UK), respectively. The isolated
islets were prepared from four to ﬁve Wistar rats in each
experiment.
2.4. Measurements of [Ca2+]i in single b-cells
Single b-cells on coverslips were mounted. [Ca2+]i in b-cells was
measured according to previous reports [17,19]. Brieﬂy, single b-
cells were superfused with HKRB at 36 C and [Ca2+]i was mea-
sured by duel-wavelength fura-2 microﬂuorometry with excitation
at 340/380 nm and emission at 510 nm using a cooled charge-cou-
pled device camera. The ratio image was produced with an Aqua-
cosmos system (Hamamatsu Photonics, Hamamatsu, Japan). In
single cell experiments, data were taken from the cells which ful-
ﬁlled the reported morphological and physiological criteria for
insulin-positive b-cells, including the diameter and responsiveness
to glucose and tolbutamide [19]. The effect of GLP-1 on [Ca2+]i wasinvestigated exclusively in the cells that responded to glucose with
increases in [Ca2+]i in a b-cell speciﬁc manner and to tolbutamide
at the end of recording. For measurements of [Ca2+]i, b-cells were
prepared from three Wistar rats in each experiment.
2.5. Statistical analysis
Data represent the mean ± s.e.m. Statistical analyses were per-
formed using the Student’s t-test for comparison between two
groups on measurements of [Ca2+]i in single b-cells or one-way AN-
OVA followed by multiple comparison tests for experiments of islet
insulin release or cAMP productions. P values below 0.05 were con-
sidered statistically signiﬁcant.
3. Results
3.1. GLP-1 enhances glucose-induced insulin release and cAMP
production in pancreatic islets and ghrelin counteracts the GLP-1
effects
In rat isolated islets under static incubation, glucose (8.3 mM)-
induced insulin release was potentiated by 10 nM GLP-1, and this
potentiation was suppressed by ghrelin at 10 nM (Fig. 1A). A rise
in glucose concentration from 2.8 to 8.3 mM stimulated cAMP pro-
duction in islets under static incubation in the presence of 500 lM
IBMX, an inhibitor of PDE. The glucose (8.3 mM)-induced cAMP
production was enhanced by GLP-1 (10 nM), and this enhancement
was blocked by ghrelin (10 nM) (Fig. 1B).
3.2. Ghrelin attenuates GLP-1-induced [Ca2+]i increases in single b-
cells
A rise in the glucose concentration from 2.8 to 8.3 mM in-
creased [Ca2+]i in rat single b-cells. After the glucose-induced
ﬁrst-phase [Ca2+]i increases were terminated, administration of
GLP-1 (10 nM) for 3 min evoked [Ca2+]i increases (Fig. 2A), conﬁrm-
ing previous report [19]. Ghrelin at 0.1 and 10 nM added 10 min
prior to GLP-1, attenuated the [Ca2+]i responses to GLP-1 (Fig. 2B
and C). The peak amplitude of GLP-1-induced [Ca2+]i increases
was decreased by ghrelin in a concentration-dependent manner
(Fig. 2D). In the presence of 16.7 mM glucose, GLP-1-induced
[Ca2+]i increases were attenuated by ghrelin at 10 nM (Fig. 2E–G).
3.3. Ghrelin inhibits forskolin-induced [Ca2+]i increases in islet single b-
cells
In the presence of 8.3 mM glucose, an adenylate cyclase activa-
tor, forskolin at 5 lM, and a membrane-permeable speciﬁc protein
kinase-A (PKA) activator, 6-Phe-cAMP at 10 lM, increased [Ca2+]i
in single b-cells (Fig. 3A and B). The peak amplitude of forskolin-in-
duced [Ca2+]i increases was signiﬁcantly (P < 0.01) suppressed by
pretreatment with 10 nM ghrelin (Fig. 3C and E), while that of 6-
Phe-cAMP-induced [Ca2+]i increases was not affected (Fig. 3D and
F).
3.4. Blockade of endogenous ghrelin potentiates GLP-1-induced insulin
release and cAMP production in isolated islets
Glucose (8.3 mM)-induced insulin release in islets was signiﬁ-
cantly enhanced by incubation with GLP-1 (10 nM) and with a
GHS-R antagonist, [D-lys3]-GHRP-6 (1 lM). Notably, the GLP-1-en-
hanced level of insulin release was further elevated by [D-lys3]-
GHRP-6 (1 lM) to a signiﬁcantly (P < 0.05) higher level (Fig. 4A).
Glucose at 5.6 mM stimulated cAMP production in islets in the
presence of 500 lM IBMX, and the glucose-induced cAMP produc-
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(1 lM). The combination of these two agents further increased the
cAMP production (Fig. 4B). Glucose (8.3 mM)-induced insulin re-
lease in isolated islets was signiﬁcantly elevated by pretreatment
with an inhibitor of GOAT, GO-CoA-Tat at 5 lM, to a level compa-
rable to that obtained with [D-lys3]-GHRP-6 (Fig. 4C vs. A).
4. Discussion
In this study, we clariﬁed the interaction between insulinostatic
peptide ghrelin and insulinotropic peptide GLP-1, and underlying
signal transduction mechanism in rat pancreatic islets and single
b-cells. GLP-1 enhanced insulin release and cAMP production in
the presence of 8.3 mM glucose in islets and increased [Ca2+]i in
the presence of 8.3 and 16.7 mM glucose in single b-cells, and all
these effects were markedly attenuated by ghrelin. Moreover,
blockade of endogenous ghrelin by [D-lys3]-GHRP-6, a GHS-R
antagonist, markedly enhanced the ability of GLP-1 to increase
insulin release and cAMP production in islets.
It is known that GLP-1 increases insulin release by increasing
[Ca2+]i in b-cells via multiple mechanisms including inhibition of
ATP-sensitive K+ (KATP) channels [21], inhibition of Kv channels
[23], and facilitation of Ca2+ inﬂux through voltage-dependent
Ca2+ channels [19,24]. These effects could be mediated by cAMP
production and cAMP-stimulated PKA-dependent and/or Epac-
dependent mechanisms [21,25]. In the present study, GLP-1 in
the presence of IBMX augmented cAMP production in islets, and
this effect was suppressed by ghrelin. GLP-1 and an adenylate cy-
clase activator forskolin evoked increases in [Ca2+]i in b-cells, and
they were attenuated by ghrelin. In contrast, [Ca2+]i responses to
6-phe-cAMP, a membrane-permeable selective activator of PKA,
were not affected by ghrelin in islet b-cells, suggesting that ghrelin
acts on the signaling process upstream but not downstream of PKA.
In our previous reports [17,18], the effects of ghrelin on the glu-
cose-induced insulin release and [Ca2+]i increases and on Kv chan-
nel currents were all blunted by treatment with an adenylate
cyclase inhibitor MDL-12330A, a cAMP analog dibutyryl-cAMP
and a PKA activator 6-phe-cAMP in perfused pancreas, isolated is-
lets and single b-cells, suggesting that ghrelin acts on the adenylate
cyclase-PKA signaling route. Taken together, our results supportthat ghrelin interacts with adenylate cyclase to inhibit its activity
and downstream PKA pathway, and that this inhibitory signaling
attenuates [Ca2+]i increases and insulin release in response to
GLP-1 (Fig. 5), although an additional involvement of Epac in the
ghrelin signaling remains to be established.
It was reported that exogenous ghrelin enhanced glucagon re-
lease from pancreatic islets and from pancreatic a-cell lines [26].
Hence, a possibility can not be excluded that a part of the effect
of ghrelin on glucose- and GLP-1-induced insulin release results
from the effect of ghrelin on glucagon release. However, it is not
highly likely since glucagon enhances insulin release and it has
been reported that GHS-R antagonist has no effect on glucagon re-
lease from isolated islets in the presence of 5.6 mM glucose [6] and
that ghrelin has no effect on glucagon release in human subjects
and perfused pancreas [27,28].
GLP-1 release into the circulation is increased after food inges-
tion and proglucagon expression is decreased by fasting [29]. Con-
versely, circulating ghrelin concentrations rise before meals and
fall after eating [30]. The present study clearly indicated opposite
actions of GLP-1 and ghrelin on insulin release, cAMP production
and [Ca2+]i in islets and b-cells. These ﬁndings by us and others
suggest that the inverse relationship between circulating concen-
trations of ghrelin and GLP-1 at both preprandial and postprandial
periods together with their reciprocal effects on insulin secretion
from islets cooperate to optimize insulin levels to achieve ﬁne glu-
cose homeostasis: it produces the ghrelin dominant state in pre-
prandial periods to effectively restrict insulin secretion and the
GLP-1 dominant state in postprandial periods to effectively pro-
mote insulin secretion for effective disposal of blood glucose.
Moreover, our present ﬁnding that ghrelin counteracts the effect
of GLP-1 suggests that it might also counteract the effect of other
hormones that also stimulate cAMP signaling in islet b-cells, which
include pituitary adenylate cyclase activating polypeptide (PACAP)
and gastric inhibitory polypeptide (GIP).
Regarding the expression of ghrelin in pancreatic islets, it has
been reported that the ghrelin immunoreactivity is localized in
a-cells of adult Wistar rat islets at 8–12 weeks old and of adult hu-
man islets [5,6], and in b-cells of adult human islets [31], and in no-
vel e-cells of adult Sprague–Dawley rat islets at 8–20 weeks [32],
and of adult human islets at 35–75 years [33,34]. Developmental
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large number of ghrelin expressing cells are observed in fetal pan-
creatic islets in mice [35], rats [32] and humans [33,34], and theysigniﬁcantly decrease in the adult pancreas or pancreatic islets in
rats [32] and humans [33,34]. Taken together, it is consistent
among the literatures that ghrelin is expressed in islet cells of adult
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lesser extent than that expressed in fetal stages. The cell species
that expresses ghrelin is reportedly a-cell, b-cell and/or e-cell,
showing a discrepancy. To support the action of ghrelin on islets
cells, GHS-R is expressed in a-cells of adult mice pancreatic islets
at 3 months old [26] and of adult rat pancreatic islets [36], and
in b-cells of adult rat pancreatic islets [36]. Both ghrelin and
GHS-R mRNAs are expressed in the adult rat pancreas at 8–
12 weeks [5] and adult human pancreas [4,31]. mRNAs for GOAT
are expressed in adult mice and rat pancreas at 8 weeks [9] and
adult human pancreas [37]. Moreover, plasma ghrelin level is high-er in the pancreatic vein than pancreatic artery in anesthetized
adult rats [12], suggesting that ghrelin is released from the pan-
creas. These documents taken together indicate that ghrelin is ex-
pressed at least in islet cells of rats at 8 weeks used in our study
and suggest that the cell types that express ghrelin and the amount
of ghrelin produced depend on the species, age and condition of
animals/humans.
In this study, [D-lys3]-GHRP-6, a GHS-R antagonist, was used for
blockade of endogenous islet-derived ghrelin. [D-lys3]-GHRP-6 en-
hanced glucose-induced insulin release and cAMP production in
rat islets as previously reported [18]. It should be mentioned that
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involvement of endogenous ghrelin but could reﬂect a possible in-
verse agonist action on GHS-R that decreases the constitutive
activity of GHS-R [38] and non-speciﬁc effects of this antagonist
on other receptors [39,40]. It has been shown by many laboratories
including us that different approaches to diminish the (effect of)
possible endogenous ghrelin consistently result in increases in
insulin secretion and associated b-cell signaling. In isolated islets,
[D-lys3]-GHRP-6, a GHS-R antagonist, and antiserum against ghre-
lin markedly increased glucose-stimulated insulin release [6] and
cAMP production [18]. The glucose-induced insulin release from
isolated islets of ghrelin knockout mice was signiﬁcantly greater
than that of wild-type mice, while basal insulin release was not al-
tered [12]. This increase in glucose-induced insulin release reﬂects
the enhanced secretory activity, because no difference was ob-
served between ghrelin knockout and wild-type mice in insulin
content per islet and expressions of insulin 1 and insulin 2 mRNAs
[12]. Moreover, pretreatment with GO-CoA-Tat, an inhibitor of
GOAT, signiﬁcantly increases insulin response to 8.3 mM glucose
in rat islets in the present study, and increases insulin response
to a glucose challenge in human islets [14]. These ﬁndings suggest
that the endogenous ghrelin suppresses glucose-induced insulin
secretion within islets of rodents and humans at least in vitro.
We found that ghrelin inhibits not only cAMP production in is-
lets but also cAMP action as evidenced by inhibition of forskolin-
induced [Ca2+]i increases, conﬁrming previous report [18]. There-fore, it is likely that the blockade of insulinostatic activity of is-
let-derived ghrelin effectively cooperates with GLP-1 in
potentiating cAMP production, thereby promoting insulin release
in islet b-cells. It has been reported that the plasma level of GLP-
1 and incretin action of GLP-1 are impaired in type 2 diabetic pa-
tients [41–43], which may contribute to reduction of insulin re-
lease. Circulating GLP-1 is rapidly degraded by DPP-4 with a half
life around 1–2 min. Currently, chemically modiﬁed DPP-4-resis-
tant GLP-1 agonists or long-acting GLP-1 analogues and DPP-4
inhibitors are clinically used in treating type 2 diabetic patients.
However, during the treatment with these incretin mimetics or
enhancers, side effects including nausea and hypoglycemia have
been reported in patients with type 2 diabetes [44]. An important
ﬁnding of the present study is that the blockade of islet-derived
ghrelin by GHS-R antagonist markedly elevates the GLP-1-induced
insulin release and cAMP production in isolated islets (Fig. 4).
These results suggest that blockade of endogenous ghrelin pro-
vides a novel tool to enhance therapeutic ability of GLP-1-based
drugs, thereby minimizing the doses of the drugs to reduce their
side effects.
In conclusion, ghrelin potently attenuates GLP-1-induced cAMP
generation, [Ca2+]i increases and insulin release in islet b-cells,
while ghrelin receptor antagonist potentiates the GLP-1-induced
cAMP generation and insulin release. These ﬁndings indicate that
interaction between ghrelin and GLP-1 plays an important role in
physiological regulation of glucose-induced insulin release in islet
Gs Gi
[Ca2+]i
Insulin secretion
GLP-1 Ghrelin
PKA
[D-Lys3]-GHRP-6
ATP cAMP 6-Phe-cAMP
Forskolin
AC
Fig. 5. The opposing effects of ghrelin and GLP-1 on islet b-cell signaling and insulin
secretion. Binding of GLP-1 to its receptor in islet b-cells stimulates the cAMP
cascade: activation of Gs protein and adenylate cyclase (AC) cause cAMP production
and PKA activation, resulting in increases in [Ca2+]i and insulin secretion.
Conversely, the ghrelin binding to GHS-R in b-cells activates Gi protein to attenuate
cAMP production, thereby counteracting the GLP-1-induced increases in [Ca2+]i and
insulin secretion. Ghrelin inhibits [Ca2+]i increases induced by an adenylate cyclase
activator forskolin but not by 6-Phe-cAMP, a PKA activator, indicating that ghrelin
suppresses AC activity but not downstream signaling of PKA in b-cells. Thus,
exogenous and endogenous ghrelin inhibit and its blockade by [D-lys3]-GHRP-6
promotes the effects of GLP-1 on cAMP, [Ca2+]i and insulin release in islet b-cells.
B. Damdindorj et al. / FEBS Letters 586 (2012) 2555–2562 2561b-cells, and suggest that ghrelin antagonism provides a novel strat-
egy to treat type 2 diabetes with dysregulated insulin release.
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